Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT01594853
Other study ID # NA_00045673
Secondary ID
Status Completed
Phase N/A
First received
Last updated
Start date May 2012
Est. completion date October 2014

Study information

Verified date December 2017
Source Hugo W. Moser Research Institute at Kennedy Krieger, Inc.
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The purpose is to see how X-linked adrenoleukodystrophy (X-ALD) is associated with strength and sensation using MRI, in women with X-ALD. The investigators will also see whether exercise can improve these symptoms for women with X-ALD.


Description:

X-linked adrenoleukodystrophy (X-ALD), a [sex-linked] progressive neurodegenerative disease, is caused by a defect in the ABCD1 gene. The disease is expressed in multiple ways, but the most common adult form is adrenomyeloneuropathy (AMN), which results in slowly progressive changes in muscle tone and weakness, sensory loss, and dysfunction of the autonomic nervous system. In a previous study the investigators linked abnormalities in the [brain/spinal cord] to lower extremity weakness in men with AMN; however, there have been no studies evaluating these relationships in women carriers (i.e., women with AMN). It is unknown, in women with AMN, how the pattern of damage in the brain and spinal cord relates to disability and if these patterns predict responsiveness to treatment. The investigators hypothesize that by using magnetization transfer (MT) and diffusion tensor imaging (DTI), two magnetic resonance imaging (MRI) modalities, to track particular changes in the brain and spinal cord will predict disability and additionally, who is likely to respond best to a training regimen. The investigators expect that these more advanced imaging techniques will be more sensitive and accurate quantitative measures of clinical motor function and women with greater loss in the spinal cord compared to the brain will benefit most from training to improve disability. To test this hypothesis, women with AMN will receive MRI scans at baseline and complete measures of global walking and lower extremity impairments of vibration sensation, spasticity, and strength at three time-points: baseline, 12 weeks, and 18 weeks after baseline. The group will participate in a resistive training program for 12 weeks. MRI data will be correlated to changes over time in measures of impairment to determine their relationships. The linking of this information will not only be important for better defining disability in women with AMN but it will also help to guide physicians and rehabilitation therapists in predicting who is likely to respond to rehabilitative interventions, as well as for optimizing the effects of future pharmacological interventions.


Recruitment information / eligibility

Status Completed
Enrollment 31
Est. completion date October 2014
Est. primary completion date October 2014
Accepts healthy volunteers Accepts Healthy Volunteers
Gender Female
Age group 21 Years to 70 Years
Eligibility Inclusion Criteria:

- confirmed diagnosis, X-ALD heterozygote carrier

- no medical contraindication to participating in a strength training program

- able to follow complex directions as determined by a score of =1 on a subset of questions taken from the NIH Stroke scale (Brott et al. 1989)

- hip flexion strength: 6.6-15.8kg

- hip extension strength: up to 18.3 kg

- normal passive range of motion at hips/knees/ankles

- able to walk =50m

Exclusion Criteria:

- Evidence of other neurological deficit that could interfere, such as previous stroke or muscle disease

- congestive heart failure

- cancer

- orthopedic conditions

- severe pain that precludes study participation

- seizures

- pregnancy

- other medical condition that precludes participation in an exercise program, e.g., unstable angina, uncontrolled diabetes, uncontrolled hypertension

Healthy controls have the same age and exclusion criteria as women with AMN except that they will not be carriers for X-ALD. They must have normal neurological function.

Study Design


Related Conditions & MeSH terms


Intervention

Behavioral:
exercise training
The exercise program uses a local Curves® gym to provide an individualized program of strength and cardiovascular training. The program is expected to be performed for 45 minutes 4-6 days per week.

Locations

Country Name City State
United States Motion Analysis Lab Baltimore Maryland

Sponsors (2)

Lead Sponsor Collaborator
Hugo W. Moser Research Institute at Kennedy Krieger, Inc. European Leukodystrophy Association

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary Change in Maximal Voluntary Contraction of the Hip Flexors From Baseline to End of Training and to Post-training Here, we will assess whether the degree of a person's white matter integrity (i.e. for tracts of interest as measured from MRI) predicts their ability to benefit from exercise. Our prediction is that those individuals with preserved white matter integrity will show the greatest improvement in hip flexor strength. Participants are assessed at baseline (visit 1, enrollment), end of training (visit 2, week 12) and post-training (visit 3, week 18).
See also
  Status Clinical Trial Phase
Not yet recruiting NCT05911919 - Validation of a Prognostic Biomarker Using Brain Diffusion MRI in X-linked Adrenoleukodystrophy
Recruiting NCT03727555 - Lentiviral Gene Therapy for X-ALD N/A
Completed NCT02595489 - A Pilot Study of Vitamin D in Boys With X-linked Adrenoleukodystrophy Phase 1
Completed NCT04687007 - SMART-ALD - A New Lifestyle Intervention to Improve Quality of Life in Women With X-linked Adrenoleukodystrophy (X-ALD) N/A
Completed NCT01165060 - The Effect of Bezafibrate on the Level of Very Long Chain Fatty Acids (VLCFA) in X-linked Adrenoleukodystrophy (X-ALD) N/A
Recruiting NCT05939232 - Registry of X-linked Adrenoleukodystrophy
Active, not recruiting NCT02699190 - LeukoSEQ: Whole Genome Sequencing as a First-Line Diagnostic Tool for Leukodystrophies
Completed NCT03864523 - Effect of Pioglitazone Administered to Patients With Adrenomyeloneuropathy Phase 2
Recruiting NCT06178120 - Disease Progression in Women With X-linked Adrenoleukodystrophy
Recruiting NCT03278899 - A Study to Prospectively Assess Disease Progression in Male Children With X-ALD
Recruiting NCT03047369 - The Myelin Disorders Biorepository Project
Recruiting NCT04675749 - Quality of Life in Women With X-linked Adrenoleukodystrophy
Withdrawn NCT03196765 - Safety, Pharmacokinetics and Pharmacodynamics of NV1205 in Pediatric Male Subjects With Adrenoleukodystrophy Phase 1/Phase 2
Withdrawn NCT01787578 - Safety and Pharmacodynamic Study of Sobetirome in X-Linked Adrenoleukodystrophy (X-ALD) Phase 1
No longer available NCT02233257 - Expanded Access for Lorenzo's Oil (GTO/GTE) in Adrenoleukodystrophy N/A